default author photo

Brett Leav

Moderna, Inc.

United States

SCHOLARLY PAPERS

2

DOWNLOADS

354

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Risk of COVID-19 after Natural Infection or Vaccination

Number of pages: 24 Posted: 01 May 2023
University of Pittsburgh - Department of Pediatrics, University of Maryland, Baltimore (UMB) - School of Medicine, Fred Hutchinson Cancer Research Center, affiliation not provided to SSRN, Fred Hutchinson Cancer Research Center, University of California, San Diego (UCSD) - Division of Infectious Diseases and Global Public Health, University of South Florida - Morsani College of Medicine, Emory University School of Medicine and Children’s Healthcare of Atlanta - Department of Pediatrics, Ndlovu Research Centre, Harvard University - Brigham and Women’s Hospital, Baylor College of Medicine, Instituto Nacional de Infectologia Evandro Chagas, Fiocruz - Lab. De Pesquisa Clinica DST/AIDS, South African Medical Research Council, University of North Carolina (UNC) at Chapel Hill - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Moderna, Inc., AstraZeneca Pharmaceuticals, Janssen Research & Development, LLC, Novavax, Inc., - Center for Vaccine Development and Global Health, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Alabama at Birmingham - Heersink School of Medicine, Harvard University - Brigham and Women’s Hospital, Government of the United States of America - Biostatistics Research Branch and - Department of Pediatrics
Downloads 228 (334,744)

Abstract:

Loading...

COVID-19, natural infection, hybrid immunity, vaccination

2.

Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial

Number of pages: 40 Posted: 29 Dec 2021
Baylor College of Medicine, Harvard University - Brigham and Women’s Hospital, Meridian Clinical Research, Duke University - Duke Human Vaccine Institute, Government of the United States of America - Vaccine Research Center, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, Government of the United States of America - VA Greater Los Angeles Healthcare System (GLA), Rutgers, The State University of New Jersey - New Jersey Medical School, Lynn Health Science Institute (Lynn Institute), DM Clinical Research - Texas Center for Drug Development (TCDD), DM Clinical Research, Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc., Moderna, Inc. and Independent
Downloads 126 (572,948)

Abstract:

Loading...

mRNA-1273, immunogenicity, antibodies, SARS-CoV-2, vaccine